medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 6

<< Back Next >>

Ann Hepatol 2016; 15 (6)

Percutaneous shunt reduction for the management of TIPS-induced acute liver decompensation: A follow-up study

De Keyzer, Bart; Nevens F, Laenen A, Heye S, Laleman W, Verslype C, van der Merwe S, Maleux G

Language: English
References: 13
Page: 911-917
PDF size: 135.97 Kb.


ABSTRACT

Background and rationale for the study. The purpose of this study was to assess the technical and clinical outcomes of transjugular intrahepatic portosystemic shunt (TIPS) reduction for the management of TIPS-induced acute liver decompensation. Between August 2000 and November 2013, 347 patients underwent a TIPS procedure in the authors’ institution; 21/347 (6%) developed post-TIPS acute liver decompensation which was managed using a percutaneous shunt reduction technique. Patient demographics, laboratory tests before and after initial TIPS and TIPS reduction, procedural data and clinical follow-up data were analysed. Results. Twenty-one patients (mean age 63 years) who underwent an initial TIPS procedure for variceal bleeding (n = 7; 33%) or refractory ascites (n = 14; 67%) successfully underwent shunt reduction ten days (3-34 days) after the initial TIPS procedure. The portosystemic pressure gradient (PSPG) increased from 8 (3-17) mmHg before reduction to 12 (7-23) mmHg after shunt reduction. Survival at one and six months follow-up was 15 (71%) and 11 patients (52%), respectively. The international normalised ratio (INR) (1.7 vs. 1.5; p = 0.044) was significantly different after TIPS reduction in the non-survival group compared to the survival group. In conclusion, TIPS reduction for the management of TIPS-induced acute liver decompensation is technically feasible and is associated with a one and six-month mortality rate of 29% and 48%, respectively. Higher post-TIPS-reduction INR values may be associated with higher risk of early mortality.


REFERENCES

  1. Suhocki P, Lungren M, Kapoor B, Kim C. Transjugular intrahepatic portosystemic shunt complication: prevention and management. Semin Intervent Radiol 2015; 32: 123-32. 2 Laleman W, Verbeke L, Meersseman P, Wauters J, van Pelt J, Cassiman D, Wilmer A, et al. Acute-on-chronic liver failure: current concepts on definition,pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Rev Gastroenterol Hepatol 2011; 5: 523-37.

  2. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, et al; CANONIC Study Investigators of the EASLCLIF Consortium. Acute-on-Chronic Liver Failure is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. Gastroenterology 2013; 144: 1426-37.

  3. Verbeke L, Nevens F, Laleman W. Bench-to-bedside review: Acute-on-chronic liver failure – linking the gut, liver and systemic circulation. Critical Care 2011; 15: 233-44.

  4. Haskal Z, Cope C, Soulen M, Shlansky-Goldberg R, Baum R, Redd D. Intentional reversible thrombosis of transjugular intrahepatic portosystemic shunts. Radiology 1995; 195: 485-8.

  5. Hauenstein K, Haag K, Ochs A, Langer M, Rössle M. The reducing stent: treatment for transjugular intrahepatic shunt-induced refractory hepatic encephalopathy and liver failure. Radiology 1995; 194: 175-9.

  6. Sze D, Hwang G, Kao J, Frisoli J, Kee S, Razavi M, Ahmed A. Bidirectionally adjustable TIPS reduction by parallel stent and stent-graft deployment. J Vasc Interv Radiol 2008; 19: 1653-8.

  7. Maleux G, Verslype C, Heye S, Wilms G, Marchal G, Nevens F. Endovascular shunt reduction in the management of transjugular portosystemic shunt-induced hepatic encephalopathy: Preliminary experience with reduction stents and stent-grafts. AJR Am J Roentgenol 2007; 188: 659-64.

  8. Cookson DT, Zaman Z, Gordon-Smith J, Ireland H, Hayes P. Management of transjugular intrahepatic portosystemic shunt (TIPS)-associated refractory hepatic encephalopathy by shunt reduction using the parallel technique: Outcomes of a retrospective case series. Cardiovasc Intervent Radiol 2011; 34: 92-9.

  9. Maleux G, Heye S, Verslype C, Nevens F. Management of transjugular intrahepatic portosystemic shunt-induced refractory hepatic encephalopathy with the parallel technique: Results of a clinical follow-up study. J Vasc Interv Radiol 2007; 18: 986-93.

  10. Maleux G, Nevens F, Wilmer A, Heye S, Verslype C, Thijs M, Wilms G. Early and long-term clinical and radiological followup results of expanded-polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunt procedures. Eur Radiol 2004; 14: 1842-50.

  11. Casadaban LC, Parvinian A, Couture PM, Minocha J, Knuttinen MG, Bui JT, Gaba RC. Characterization of liver function parameter alterations after transjugular intrahepatic portosystemic shunt creation and association with early mortality. AJR Am J Roentgenol 2014; 203: 1363-70.

  12. Casadaban L, Gabra M, Parvinian A, Minocha J, Knuttinen M, Bui J, Gaba R. Impact of transjugular intrahepatic portosystemic shunt creation on intermediate-term model for endstage liver disease score progression. Transplant Proc 2014; 46: 1384-8.

  13. Gaba R, Couture P, Bui J, Knuttinen M, Walzer N, Kallwitz E, Berkes J, et al. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol 2013; 24: 411-20, 420.e1-4; quiz 421.




2020     |     www.medigraphic.com